MedTrace Logo

A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

NCT06169995 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-12-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in Upper Gastrointestinal Endoscopy

Conditions

  • Sedation in the Upper Gastrointestinal Endoscopy

Interventions

DRUG

Remimazolam Tosilate

bolus dose: 5mg，IV supplemental dose: 2.5mg，IV

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2023-12-15
Completion
2023-12-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06169995 on ClinicalTrials.gov